Effective.

Doesn’t mean cost-effective. This week the FDA approved the combo ipi + nivo to be given indefinitely for hepatocellular carcinoma progressing after first-line sorafenib based on an objective response in one-third of such patients enrolled on CheckMate 040. | FDA 2020